What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
After the company presented data on its chimeric antigen receptor T-cell therapy (CAR-T), JCAR017, at the annual American Society of Hematology conference over the weekend, Juno Therapeutics (NASDAQ: JUNO) shares are losing 11.9% of their value at 2 p.m. EST Monday.
Juno Therapeutics reported arguably best-in-class safety for JCAR017 in non-Hodgkin lymphoma at the conference, but investors appear disappointed that response rates weren't higher.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
